WNS (Holdings) Limited WNS

Set alert

Price alert · WNS

All alert types
76.48 0.00 0.00%

At close · Oct 16

76.39 Day range 76.48
42.68 52-week range 76.48
YTD
+61.38%
1 year
+53.91%
Open
76.40
Prev close
76.48
Mkt cap
3.29B
Vol
2.85M
Avg vol
979.24K
EPS
3.58
P/E
21.36
Div yield
0.00%
More statistics
Low
76.39
High
76.48
Forward P/E
16.17
Beta
0.92
Short ratio
1.51
Inst. own
97.56%
Dividend
0.00
Ex-div date
Earnings
Oct 16, 2025
50-d avg
75.75
200-d avg
65.17
1y target
76.00

5D chart

Chart tools
Interval

Chart is warming up

The five-day price history for WNS has not been loaded yet. Try again in a moment.

Discussion (6)

Sign in to join the discussion

Peter Freeman WNS 1 year ago #1

Are you having issues trading you don't have to panic Laura Ben Wesley on ???????? has got you covered, with $2000 I make over $8500 weekly thank you ma'am, write her via her ???????? +1(541)310-7087

Dave Steven WNS 1 year ago #2

trading on your own is not advisable, for good returns trade with a pro like Laura Ben Wesley on ???????? with less capital make monthly profits, she helped me acquire $20K in two weeks, Message Laura Ben Wesley via her ????????+1(541)310-7087

VICKY HANUKA WNS 3 years ago #3

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.

Scott Miller WNS 3 years ago #5

$ WNS classic Needham dump, leading into their Tuesday pump. ?